Patient characteristics
| Variable . | Overall N = 44 . | Low CMV IgG N = 13 . | High CMV IgG N = 31 . | P value . |
|---|---|---|---|---|
| Age (y), median (range) at the time of CAR-T | 64 (36-76) | 63 (47-73) | 64 (36-76) | .32 |
| Sex, n (%) | ||||
| Female | 15 (34.1) | 5 (38.5) | 10 (32.3) | .74 |
| Male | 29 (65.9) | 8 (61.5) | 21 (67.7) | |
| MM subtype, n (%) | ||||
| IgG | 24 (54.5) | 8 (61.5) | 16 (51.6) | 1.00 |
| IgA | 8 (18.2) | 2 (15.4) | 6 (19.4) | |
| IgD | 1 (2.3) | 0 (0) | 1 (3.2) | |
| Bence–Jones | 11 (25.0) | 3 (23.1) | 8 (25.8) | |
| R2-ISS stage at CAR-T, n (%) | ||||
| Stage 1 | 6 (13.6)) | 4 (30.8) | 2 (6.5) | .20 |
| Stage 2 | 14 (31.8) | 3 (23.1) | 11 (35.5) | |
| Stage 3 | 22 (50) | 6 (46.2) | 16 (51.6) | |
| Stage 4 | 1 (2.3) | 0 (0) | 1 (3.2) | |
| Unknown | 1 (2.3) | 0 (0) | 1 (3.2) | |
| MyCARe, n (%) | ||||
| Low | 12 (27.3) | 5 (38.5) | 7 (22.6) | .49 |
| Intermediate | 29 (65.9) | 7 (53.8) | 22 (71.0) | |
| High | 3 (6.8) | 1 (7.7) | 2 (6.5) | |
| CMV IgG (AU/mL), median (range) | 187.15 (20.6-250) | 64.7 (20.6-113.2) | 238.2 (115.6-250) | <.001 |
| Previous treatment lines, median (range) | 3 (2-10) | 3 (2-6) | 3 (2-10) | .50 |
| Previous autologous stem cell transplantation, n (%) | 26 (59.1) | 9 (69.2) | 17 (54.8) | .51 |
| Extramedullary disease, n (%) | 6 (14.3) | 1 (7.7) | 5 (17.2) | .65 |
| Triple-class refractory∗, n (%) | 33 (75.0) | 12 (92.3) | 21 (67.7) | .13 |
| Penta refractory†, n (%) | 3 (6.8) | 1 (7.7) | 2 (6.5) | 1 |
| High-risk cytogenetic abnormality until CAR-T therapy, n (%) | ||||
| High-risk | 31 (72.1) | 8 (61.5) | 23 (74.2) | .46 |
| del(17p) | 13 (29.5) | 3 (23.1) | 10 (32.3) | .72 |
| t(4;14) | 9 (20.5) | 2 (15.4) | 7 (22.6) | .70 |
| t(14;16) | 1 (2.3) | 1 (7.7) | 0 (0) | .21 |
| 1q abnormality | 28 (63.6) | 7 (53.8) | 21 (67.7) | .30 |
| Tocilizumab use for CRS, n (%) | 44 (100) | 13 (100) | 13 (100) | 1 |
| Steroid use for CRS, n (%) | 29 (65.9) | 7 (53.8) | 22 (71.0) | .31 |
| Variable . | Overall N = 44 . | Low CMV IgG N = 13 . | High CMV IgG N = 31 . | P value . |
|---|---|---|---|---|
| Age (y), median (range) at the time of CAR-T | 64 (36-76) | 63 (47-73) | 64 (36-76) | .32 |
| Sex, n (%) | ||||
| Female | 15 (34.1) | 5 (38.5) | 10 (32.3) | .74 |
| Male | 29 (65.9) | 8 (61.5) | 21 (67.7) | |
| MM subtype, n (%) | ||||
| IgG | 24 (54.5) | 8 (61.5) | 16 (51.6) | 1.00 |
| IgA | 8 (18.2) | 2 (15.4) | 6 (19.4) | |
| IgD | 1 (2.3) | 0 (0) | 1 (3.2) | |
| Bence–Jones | 11 (25.0) | 3 (23.1) | 8 (25.8) | |
| R2-ISS stage at CAR-T, n (%) | ||||
| Stage 1 | 6 (13.6)) | 4 (30.8) | 2 (6.5) | .20 |
| Stage 2 | 14 (31.8) | 3 (23.1) | 11 (35.5) | |
| Stage 3 | 22 (50) | 6 (46.2) | 16 (51.6) | |
| Stage 4 | 1 (2.3) | 0 (0) | 1 (3.2) | |
| Unknown | 1 (2.3) | 0 (0) | 1 (3.2) | |
| MyCARe, n (%) | ||||
| Low | 12 (27.3) | 5 (38.5) | 7 (22.6) | .49 |
| Intermediate | 29 (65.9) | 7 (53.8) | 22 (71.0) | |
| High | 3 (6.8) | 1 (7.7) | 2 (6.5) | |
| CMV IgG (AU/mL), median (range) | 187.15 (20.6-250) | 64.7 (20.6-113.2) | 238.2 (115.6-250) | <.001 |
| Previous treatment lines, median (range) | 3 (2-10) | 3 (2-6) | 3 (2-10) | .50 |
| Previous autologous stem cell transplantation, n (%) | 26 (59.1) | 9 (69.2) | 17 (54.8) | .51 |
| Extramedullary disease, n (%) | 6 (14.3) | 1 (7.7) | 5 (17.2) | .65 |
| Triple-class refractory∗, n (%) | 33 (75.0) | 12 (92.3) | 21 (67.7) | .13 |
| Penta refractory†, n (%) | 3 (6.8) | 1 (7.7) | 2 (6.5) | 1 |
| High-risk cytogenetic abnormality until CAR-T therapy, n (%) | ||||
| High-risk | 31 (72.1) | 8 (61.5) | 23 (74.2) | .46 |
| del(17p) | 13 (29.5) | 3 (23.1) | 10 (32.3) | .72 |
| t(4;14) | 9 (20.5) | 2 (15.4) | 7 (22.6) | .70 |
| t(14;16) | 1 (2.3) | 1 (7.7) | 0 (0) | .21 |
| 1q abnormality | 28 (63.6) | 7 (53.8) | 21 (67.7) | .30 |
| Tocilizumab use for CRS, n (%) | 44 (100) | 13 (100) | 13 (100) | 1 |
| Steroid use for CRS, n (%) | 29 (65.9) | 7 (53.8) | 22 (71.0) | .31 |
MM, multiple myeloma; MyCARe, Myeloma CAR-T Relapse model; R2-ISS, Second Revision of the International Staging System.
Triple-class refractory is defined as refractory to proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibody.
Penta refractory is defined as refractory to 2 proteasome inhibitors, 2 immunomodulatory drugs, and anti-CD38 antibody.